1.
Inflamm Bowel Dis
; 7(1): 34-7, 2001 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-11233658
RESUMO
Infusion of the antitumor necrosis factor-alpha chimeric monoclonal antibody infliximab is highly effective in the treatment of refractory and fistulizing Crohn's disease (CD), but can be associated with the development of severe allergic reactions during retreatment, precluding further use of the medication. We present two CD patients (one adult and one child) with a history of anaphylactic/anaphylactoid reactions to retreatment with infliximab who subsequently underwent successful desensitization and therapeutic infusion using parenteral dose escalation in an intensive care unit setting.
Assuntos
Anafilaxia/etiologia , Anticorpos Monoclonais/uso terapêutico , Doença de Crohn/tratamento farmacológico , Doença de Crohn/imunologia , Dessensibilização Imunológica/métodos , Adulto , Anticorpos Monoclonais/administração & dosagem , Anticorpos Monoclonais/efeitos adversos , Criança , Feminino , Fármacos Gastrointestinais , Humanos , Infliximab , Unidades de Terapia Intensiva , Masculino
2.
Ann Allergy Asthma Immunol
; 85(6 Pt 1): 450-6, 2000 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-11190255
3.
Circulation
; 34(6): 1034-43, 1966 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-5928549